Roche Holding AG (RHHBY), a Swiss healthcare company, Tuesday announced that it has signed a definitive merger agreement to acquire Poseida Therapeutics, Inc. (PSTX) for $9 per share in cash at closing.
The transaction is expected to close in the first quarter of 2025.
Roche will start a tender offer to acquire Poseida's outstanding shares for $9.00 per share in cash at closing, plus a contingent value right or CVR offering milestone payments up to $4.00 per share in cash.
The deal values Poseida at approximately $1 billion at closing, with the deal potentially reaching $1.5 billion. The closing price represents a 215% premium over Poseida's November 25 share price.
Roche said the acquisition would help it to create new, advanced treatments for oncology, immunology, and neurology, making it at the forefront of off-the-shelf cell therapies.
Roche and Poseida already work together on CAR-T cell therapies for blood cancers, and this deal strengthens their partnership which started in 2022.
PSTX had closed its regular trading at 4.76% higher at $2.86 on the Nasdaq. In the extended trading, PSTX grew 11.19% further to $3.18.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.